Alnylam Pharmaceuticals | ALNY - Current Liabilities


Alnylam Pharmaceuticals reported $1.35B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Takeda JPY 2.43T 180.65B Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026